Inovio Pharmaceuticals, Inc. is a leading biotechnology company that specializes in the development of DNA medicines that treat and safeguard individuals from diseases associated with human papillomavirus, cancer, and infectious diseases. The company's DNA medicines platform uses SynCon to target and optimize the DNA sequence of the antigen and CELLECTRA to deliver the DNA plasmids. Inovio Pharmaceuticals is currently working on several clinical studies of its DNA medicines, including VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, INO-3107 for HPV-related respiratory rapillomatosis, and INO-5401 for glioblastoma multiforme. The company has partnerships and collaborations with many well-known organizations, including AstraZeneca, The Bill & Melinda Gates Foundation, and Regeneron Pharmaceuticals. Inovio Pharmaceuticals was founded in 1983 and is headquartered in Pennsylvania.
Inovio Pharmaceuticals's ticker is INO
The company's shares trade on the NASDAQ stock exchange
They are based in Plymouth Meeting, Pennsylvania
There are 51-200 employees working at Inovio Pharmaceuticals
It is inovio.com/about-inovio/mission-and-values
Inovio Pharmaceuticals is in the Healthcare sector
Inovio Pharmaceuticals is in the Biotechnology industry
The following five companies are Inovio Pharmaceuticals's industry peers: